<span data-sheets-value= "{"1":2,"2":"

This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

<span data-sheets-value= "{"1":2,"2":"

This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

<span data-sheets-value= "{"1":2,"2":"

This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

<span data-sheets-value= "{"1":2,"2":"

This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.

Coverage of stories discussed this week on ascopost.com:

Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease